- Visibility 327 Views
- Downloads 24 Downloads
- Permissions
- DOI 10.18231/j.ijpp.2020.006
-
CrossMark
- Citation
Comparative study analyzing efficacy and safety of sitagliptin with metformin versus glimepiride with metformin on patients of type-2 diabetes mellitus
- Author Details:
-
Ved Prakash *
-
Nidhi Goel
-
Sunil Verma
Introduction: Type 2 Diabetes Mellitus (T2DM) a serious, common chronic disease constituting a major public health issue worldwide. Yet no cure is available, education of populace is still the key to control this emerging epidemic. Novel drugs are being developed, some used as monotherapy or in-combination for effective glycaemic control.
Objective: Comparing the efficacy of Sitagliptin+Metformin versus Glimepiride+ Metformin on patients of T2DM.
Material and method: 30 weeks open labeled Randomized controlled study enrolling 80 patients of T2DM, divided into two groups with 40 patients in each. Group A given Metformin(500mg) with Sitagliptin(100mg) and group B given Metformin(500mg) with Glimepiride(1mg). HbA1c, FBG, PPBG were done at baseline, 15 and 30 weeks.
Results: Group A and Group B both leads to significant (<0>0.05) for FBG, PPBG at 15 and 30 weeks and HbA1c at 15weeks but was the difference was statistically significant (<0>
Conclusion: Sitagliptin with Metformin and Glimepiride with Metformin both causes efficient glycaemic control with no significant adverse reaction but the gylcaemic control of patients taking Sitagliptin with Metformin was slightly better as compared to patients taking Glimepiride with Metformin. Thus concluding Sitagliptin to be more efficacious than Glimepiride.
Keywords: Diabetes mellitus type II, Sitagliptin, Glimepiride, Metformin, HbA1c (glycosylated haemoglobin), Fasting blood glucose, Post-prandial blood glucose.
References
- Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: a review of current trends. Oman Med J. 2012;27:269-73.
- Kharroubi AT, Darwish HM. Diabetes mellitus: The epidemic of the century. World J Diabetes. 2015;6:850-67.
- Tabish SA. Is diabetes becoming the biggest epidemic of the twenty-first century? Int J Health Sci. 2007;1(2):5-8.
- Wu Y, Ding Y, Tanaka Y, Zhang W. Risk factors contributing to Type 2 diabetes and recent advances in the treatment and prevention. Int J Med Sci. 2014;11(11):1185-1200.
- Piero MN, Nzaro GM, Njagi JM. Diabetes mellitus – a devastating metabolic disorder. Asian J Biomed Pharm Sci. 2014;4(40):1-7.
- Kidambi S, Patel SB. Diabetes mellitus: Considerations for dentistry. J Am Dent Assoc. 2008;139:8S–18S.
- Thrasher J. Pharmacologic management of type 2 diabetes mellitus: available therapies. Am J Med. 2017;130:S4–S17.
- Mahler RJ, Adler ML: Type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment. J Clin Endocrinol Metab. 1999;84:1165-71.
- Litwak L, Goh SY, Hussein Z, Malek R, Prusty V, Khamseh ME. Prevalence of diabetes complications in people with type 2 diabetes mellitus and its association with baseline characteristics in the multinational A1chieve study. Diabetol Metab Syndr. 2013;5:57.
- Elgzyri T. Basic Management of Diabetes Mellitus: Practical guidelines. Libyan J Med. 2006;1(2):AOP:060813.
- Nakamura I, Oyama J, Komoda H, Shiraki A, Sakamoto Y, Taguchi I, et al. Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: A preliminary report. Cardiovasc Diabetol 2014;13:5.
- Singh P, Choudhary R, Singh VK, Matreja PS. Comparison of metabolic effects of glimepride and sitagliptin with metformin in patients suffering from type 2 diabetes mellitus in a tertiary care hospital. Int J Basic Clin Pharmacol. 2019;8:1467-72.
- Sakura H. Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study. BMC Endocr Disord. 2016;16(1):70.
- Aschner P, Katzeff HL, Guo S, Sunga S. Williams‐Herman D, Kaufman KD, et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes, Obes Metab. 2009;12(3):252-61.
- Jothydev K, Pradeep B, Sadasivan P, Arun S. Sitagliptin 100mg vs glimepiride 1–3mg as an add-on to insulin and metformin in type 2 diabetes (SWIM). Endocr Connect. 2017;6(8):748-57.
- Sharma M, Sonawane R, Marko JL. Comparative study of efficacy and safety of sitagliptin versus glimepiride in patients of type-2 diabetes mellitus inadequately controlled with metformin alone. Int J Adv Med. 2016;3:564-8.
- Devarajan TV, Venkataraman S, Kandasamy N, Oomman A, Boorugu HK, Karuppiah S, et al. Comparative evaluation of safety and efficacy of glimepiride and sitagliptin in combination with metformin in patients with type 2 diabetes mellitus: Indian multi centricrandomized trial - START Study. Indian J Endocr Metab. 2017;21:745-50.
- Liu D, Jin B, Chen W, Yun P. Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta- analysis. BMC Pharmacol Toxicol. 2019;20:15.
How to Cite This Article
Vancouver
Prakash V, Goel N, Verma S. Comparative study analyzing efficacy and safety of sitagliptin with metformin versus glimepiride with metformin on patients of type-2 diabetes mellitus [Internet]. Indian J Pharm Pharmacol. 2020 [cited 2025 Sep 30];7(1):26-33. Available from: https://doi.org/10.18231/j.ijpp.2020.006
APA
Prakash, V., Goel, N., Verma, S. (2020). Comparative study analyzing efficacy and safety of sitagliptin with metformin versus glimepiride with metformin on patients of type-2 diabetes mellitus. Indian J Pharm Pharmacol, 7(1), 26-33. https://doi.org/10.18231/j.ijpp.2020.006
MLA
Prakash, Ved, Goel, Nidhi, Verma, Sunil. "Comparative study analyzing efficacy and safety of sitagliptin with metformin versus glimepiride with metformin on patients of type-2 diabetes mellitus." Indian J Pharm Pharmacol, vol. 7, no. 1, 2020, pp. 26-33. https://doi.org/10.18231/j.ijpp.2020.006
Chicago
Prakash, V., Goel, N., Verma, S.. "Comparative study analyzing efficacy and safety of sitagliptin with metformin versus glimepiride with metformin on patients of type-2 diabetes mellitus." Indian J Pharm Pharmacol 7, no. 1 (2020): 26-33. https://doi.org/10.18231/j.ijpp.2020.006